04/12/2012Support is growing for IDSA’s proposed new antibiotic approval pathway, which would provide a new approval option for companies interested in developing drugs for serious infections with few or no existing treatment options.
03/21/2012IDSA’s new rhinosinusitis clinical practice guidelines are intended to help doctors distinguish between bacterial and viral causes of sinus infections.
03/15/2012In a new position paper, IDSA, SHEA, and PIDS urge health care systems and policymakers to step up efforts to protect patients by preserving the effectiveness of available antibiotics through antimicrobial stewardship.
03/08/2012The Infectious Diseases Society of America (IDSA) proposed the new pathway, called the “Limited Population Antibacterial Drug (LPAD)” mechanism, to provide an important new approval option for companies interested in developing drugs to treat patients with serious infections where few or no treatment options exist.
02/23/2012Lifesaving Antibiotics Needed Now 2012-02-23 /2012_Lifesaving_Antibiotics_Needed_Now/ Broad Coalition Implores Congress to Approve Legislation Encouraging Development of New Drugs to Treat Deadly Bacterial Infection [February 23, 2012, WASHINGTON] – Congress must seize the opportunity this year in “must
02/17/2012President’s FY2013 Budget Is a Mixed Bag for Infectious Diseases 2012-02-17 The Infectious Diseases Society of America (IDSA) is deeply concerned about cuts proposed in President Obama’s Fiscal Year (FY) 2013 proposed budget for our nation’s immunization programs, state and local public health preparednes